ストックスクリーナーアプリを入手
15.46
15.37%
2.06
前日終値:
$13.40
開ける：
$13.69
24時間の取引高:
15.15M
Relative Volume:
1.68
時価総額：
$3.12B
収益：
-
当期純損益:
$-29.46M
株価収益率:
-67.72
EPS:
-0.2283
ネットキャッシュフロー:
$-28.17M
1週間 パフォーマンス:
+20.97%
1か月 パフォーマンス:
+19.84%
6か月 パフォーマンス:
+272.53%
1年 パフォーマンス:
+778.41%
1日の値動き範囲:
$13.26
$15.67
1週間の範囲:
$12.39
$15.67
52週間の値動き範囲:
$1.39
$15.88
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
名前
Sellas Life Sciences Group Inc
セクター
電話
(646) 200-5278
住所
7 TIMES SQUARE, NEW YORK, NY
Compare SLS vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
15.46 | 2.71B | 0 | -29.46M | -28.17M | -0.2283 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-07-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-11-01 | 開始されました | Oppenheimer | Outperform |
| 2018-04-02 | 開始されました | H.C. Wainwright | Buy |
| 2018-03-19 | アップグレード | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc (SLS) 最新ニュース
Are SELLAS Life Sciences (SLS) Loss Trends Masking a Shifting Cancer Vaccine Investment Narrative? - simplywall.st
Sellas Life Sciences Rides a Sector Wave as Its Own Leukemia Trial Hits the Home Stretch - Ad-hoc-news.de
SLS Stock Extends Rally Overnight: CEO Says ‘Bullish’ Leukemia Data Could Drive NCCN Recognition For GPS - Stocktwits
SLS Stock Clocks Three Straight Weeks Of Gains On Cancer Vaccine Spillover, REGAL Trial Data Anticipation - Yahoo Finance
SELLAS Shares Climb 15% as Market Values Company $2.98 Billion Over Cash Pre-AML Update - TechStock²
Sebring Design Build Featured in Newsweek on Why Affluent Williamson County Homeowners Are Remodeling Instead of Moving - Yahoo Finance
Why SELLAS Life Sciences Group (SLS) Stock Is Up Today - Quiver Quantitative
SLS, IBRX Eye Green Month As Biotech ETF Gains Steam: Analyst Sees ‘Continued Opportunities’ In Immuno-Oncology - Stocktwits
10 Health Care Stocks Whale Activity In Today’s Session - Benzinga
3 Healthcare Funds to Play Safe as Fed Readies for Rate Hike - Yahoo Finance
SELLAS Soars as Leukemia Trial Readout Sparks Speculation - TipRanks
Can STERIS Stock Deliver as Its $600 Million Chemistry Bet Scales? - Yahoo Finance
OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission - Yahoo Finance
Citadel Sold More Than $4 Billion of Situational Awareness Bets - Yahoo Finance
Is the Options Market Predicting a Spike in Latham Group Stock? - Yahoo Finance
IQVIA Holdings Stock Outlook: Is Wall Street Bullish or Bearish? - Yahoo Finance
Goldman Says Slowing Inflation Is Best Path to Lower US Yields - Yahoo Finance
Is SELLAS (SLS) Turning Sector Hype Into a Durable Cancer Vaccine Story Despite Ongoing Losses? - Yahoo Finance
SELLAS Life Sciences Soars 7.9x in Three Years, But Valuation Screens as Stretched - finance.biggo.com
SELLAS Life Sciences Group (SLS) Shares Just Moved, So What Is Drawing Attention? - Yahoo Finance
SELLAS Life Sciences Group (SLS) Stock Looks Stretched Despite Key AML Trial Progress - Yahoo Finance
SLS Stock Pops Big After Hours On Imminent Leukemia Trial Data Readout Optimism - Stocktwits
SLS Stock Edges Higher As Wall Street, Retail Expect Another MRNA Moment - Stocktwits
SLS Stock Tests $5 Again: Retail Targets ‘No’ Vote On 20M Share Dilution Push Before AML Trial Results - Stocktwits
SLS Stock Slides Premarket: Traders Brace For Key Arbitration Ruling In GPS China Payment Dispute - Stocktwits
Maxim Group Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Maintains Target Price $30 - Moomoo
SLS Stock Kicks Off Week In Green: CEO Flags Role In EU Biotech Policy Talks That Could Impact Drug Approvals - Stocktwits
SLS Short Interest Hits All-Time High: Sellas Bulls Smell A Short Squeeze As Executive Contract Changes Fuel Buyout Chatter - Stocktwits
Sellas Life Sciences Draws Significant Retail Buzz As Traders Eye REGAL Phase 3 Catalyst – SLS Stock Soars 15% - Stocktwits
SLS Stock Rises Overnight: Retail Traders Call New AML Survival Data 'Huge' Ahead Of CEO’s Fox Appearance - Stocktwits
SLS Stock Rises Overnight: Traders Rally Behind Jim Cramer's 'Two Thumbs Up' Call Ahead Of Key AML Readout - Stocktwits
SLS Stock Surges Toward Fifth Weekly Rise: CEO Touts GPS As Lifeline For Elderly Patients As Cancer Summit Looms - Stocktwits
SLS Stock Jumps Premarket: CEO Says GPS AML Data Has ‘Very Good Chance’ To Beat Earlier Survival Outcomes - Stocktwits
SLS Stock Hits Over 4-Year High: CEO Eyes FDA Talks, ‘Whole Gamut’ Of Cancer Uses For GPS - Stocktwits
SLS Stock Sparks Retail Buzz Ahead of AACR Presentation On Experimental Cancer Therapy - Stocktwits
Why Did SLS, BB, OUST Stocks Surge To 52-Week Highs Today? - Stocktwits
SELLAS Life Sciences Group, Inc. (SLS) Latest Stock News & Headlines - Yahoo Finance
SELLAS Life Sciences Group (SLS) Nears Key Phase 3 Readout On A Pricey Valuation - simplywall.st
SLS Stock Pops After-Hours As Loss Shrinks, Cash Swells — All Eyes On High Stakes AML Trial In 'Pivotal' 2026 - Stocktwits
SLS Stock Surges Into Conference Season As Investors Hunt For AML Readout Hints - Stocktwits
SLS Stock Tanks Hard: Retail Traders Blame Warrant Holders, 'Flippers' Cashing Out Before AML Catalyst - Stocktwits
Sellas’ Experimental Drug SLS009 Appears To Be Leading The CDK9 Race, Says Alliance Global – Analyst Sees About 200% Upside Potential - Stocktwits
SLS Stock Hits Over 3-Year High As AML Drug Trial Nears Final Readout — Wall Street Sees 30% More Upside - Stocktwits
GOOGL Stock Drops In Premarket: Report Says Search Giant Trims Cloud Team Amid AI Spending Push - Stocktwits
SLS Stock Hits Over 5-Year High: Retail Traders Bet Big On Breaking $25 As AML Readout Looms - Stocktwits
SLS Stock Extends Rally To 4 Days: Jefferies Discloses New Stake, CEO Signals AML Database-Lock Preparations - Yahoo Finance
Sellas CEO Angelos Stergiou Highlights Pediatric Leukemia Study That ‘Directly Supports’ Scientific Basis Of Regal Trial - Stocktwits
Sellas Life Sciences Group Inc (SLS) 財務データ
収益
当期純利益
現金流量
EPS
1.21%
1.07%
大文字化:
|
ボリューム (24 時間):